- Home
- SMSI vs BLRX Comparison
SMSI vs BLRX Comparison
Compare SMSI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SMSI | BLRX |
|---|---|---|
| Founded | 1982 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 12.6M |
| IPO Year | 2017 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SMSI | BLRX |
|---|---|---|
| Price | $0.81 | $2.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | ★ 344.6K | 8.4K |
| Earning Date | 03-04-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,363,000.00 | N/A |
| Revenue This Year | $61.84 | N/A |
| Revenue Next Year | $58.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.41 | $2.30 |
| 52 Week High | $1.30 | $7.77 |
Technical Indicators
Market Signals| Indicator | SMSI | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.97 | 44.86 |
| Support Level | $0.67 | $2.66 |
| Resistance Level | $0.82 | $3.93 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 76.00 | 33.76 |
Price Performance
Historical ComparisonAbout SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.